You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 121 No. 12, December 2003 TABLE OF CONTENTS
  Archives
  •  Online Features
  Clinicopathologic Reports, Case Reports, and Small Case Series
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (1)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Ocular/ Adnexal Tumors
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Intraocular Melanocytoma in Association With Bone Formation

Arch Ophthalmol. 2003;121:1791-1794.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Intraocular melanocytoma is an uncommon tumor. To our knowledge, in none of the cases reported to date, either individually or in case series, has this tumor been associated with bone formation. We report 2 such cases.

Report of Cases.

Case 1. A 14-year-old white girl had pain in her left eye of 5 weeks' duration. There was no history of ocular trauma or disease. Her visual acuity was 20/60 OS, and the intraocular pressure was 11 mm Hg. There was no evidence of glaucoma or uveitis. The lens was displaced inferonasally by a superotemporal ciliary body mass.

Local resection of this mass was performed with deep scleral lamellar dissection. Postoperatively, the visual acuity was 20/60 OS; 6 months later, it had decreased to 20/200 OS because of ocular hypotony, macular edema, and epimacular membrane formation. The hypotony resolved with a short course of systemic steroids. At the last follow-up visit (28 months . . . [Full Text of this Article]


Comment.
Paul Hiscott, MD
Liverpool, England

R. Jean Campbell, MD; Dennis M. Robertson, MD
Rochester, Minn

Bertil Damato, MD
Liverpool

Corresponding author: R. Jean Campbell, MD, Department of Ophthalmology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.